Ombitasvir
Ombitasvir[edit]
Ombitasvir is an antiviral drug used in the treatment of hepatitis C. It is a part of a combination therapy that targets the hepatitis C virus (HCV) by inhibiting the NS5A protein, which is essential for viral replication. Ombitasvir is often used in combination with other antiviral agents such as paritaprevir, ritonavir, and dasabuvir to enhance its efficacy.
Mechanism of Action[edit]
Ombitasvir works by inhibiting the NS5A protein of the hepatitis C virus. NS5A is a non-structural protein that plays a crucial role in the replication of the viral RNA and the assembly of the virus. By binding to NS5A, ombitasvir disrupts these processes, thereby reducing the viral load in the patient's body.
Clinical Use[edit]
Ombitasvir is used in combination with other antiviral medications to treat chronic hepatitis C infection. The specific combination and duration of treatment depend on the genotype of the virus and the presence of other conditions such as cirrhosis.
Combination Therapy[edit]
Ombitasvir is commonly used in a fixed-dose combination with paritaprevir, ritonavir, and dasabuvir, marketed under the brand name Viekira Pak. This combination is effective against HCV genotype 1, which is the most common genotype in many regions.
Side Effects[edit]
The use of ombitasvir in combination therapy can lead to side effects, which may include:
- Fatigue
- Nausea
- Itching
- Insomnia
- Anemia
Patients are advised to report any severe or persistent side effects to their healthcare provider.
Pharmacokinetics[edit]
Ombitasvir is administered orally and is absorbed into the bloodstream, where it reaches peak concentrations within a few hours. It is metabolized in the liver and excreted primarily in the feces.
